medigraphic.com
ISSN 0016-3813 (Impreso)

2003, Número 1

<< Anterior Siguiente >>

Gac Med Mex 2003; 139 (1)


Productos finales de glicación avanzada y complicaciones crónicas de la diabetes mellitus

Méndez JD

Idioma: Español
Referencias bibliográficas: 51
Paginas: 49-55
Archivo PDF: 86.20 Kb.


RESUMEN

Objetivo: Revisar en la literatura los avances de la investigación científica en el área de diabetes y sus complicaciones con énfasis particular en el papel que juegan los productos finales de la glicación avanzada (AGEs) en la fisiopatología de las complicaciones crónicas de la diabetes mellitus. Materiales: Se hizo una selección de los artículos más relevantes sobre este tema, entre los obtenidos en una búsqueda en la base de datos MEDLINE que comprendió de 1985 al 2000. Resultados:La hiperglucemia causa complicaciones irreversibles macro y microvasculares entre las que se incluyen retinopatía, nefropatía, aterosclerosis, y enfermedad cerebrovascular. Hay evidencia suficiente de que la glicación conduce a modificaciones químicas de proteínas y otras macromoléculas y que esto contribuye a la patogénesis de las complicaciones diabéticas. Se han identificado varios AGEs y sus receptores correspondientes. La inhibición de la formación de AGEs está bajo intensa investigación a fin de prevenir las complicaciones diabéticas. De todos los inhibidores, las amadorinas parecen tener mayor potencial terapéutico. Conclusiones:Se sabe que un grupo heterogéneo de AGEs se forma por glicación. El mecanismo de formación se ha dilucidado parcialmente, lo que ha dificultado la identificación del producto o los productos precisos que ocasionan el daño in vivo, y también el desarrollo de inhibidores específicos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Brownlee M, Cerami A. The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem.1981; 50:385-432.

  2. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosilation and the pathogenesis of diabetic complications. Ann Int Med.1984;101(4):527-537.

  3. Green DA. Metabolic abnormalities in diabetic peripheral nerve: relation to impaired function. Metabolism 1983;32: 118-123.

  4. Clements RS Jr. The role of abnormal polyol metabolism in diabetic complications. En: Brodoff BN, Bleicher SJ. Diabetes Mellitus and Obesity. Baltimore Williams and Wilkins USA, 1982,pp 117-128.

  5. Koenig RJ, Cerami A. Hemoglobin A1c and diabetes mellitus. Annu Rev Med 1980; 31:29-34.

  6. Monier VM. Toward a Maillard reaction theory of aging. In: The Maillard reaction in aging, Diabetes, and Nutrition. Baynes JW, Monier VM.Eds.Progress in Clinical and Biological Research Vol. 34 Alan R.Liss, Inc. New York. 1989. Pp 1-22.

  7. Miller JA, Gravallese E, Bunn HF. Nonenzymatic glycosylation of eritrocyte membrane proteins:relevance to diabetes. J Clin Invest 1980;65:896-901.

  8. Munch G, Colaco C.Towards a new age of the chemistry and pathophysiology of the Maillard reaction. Cell Mol Biol.1998; 44(7):ix-x.

  9. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lions TJ, McCance DR, Baynes JW.Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993;91:2463-2469.

  10. Vitek MP, Bhattyacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A. Advanced glycation endproducts contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 1994;91:4766-4770.

  11. Frie EB, Dehenhart TP, Thorpe SR, Baynes JW. Role of the Maillard reaction in aging of tissue proteins.J Biol Chem.1998;273(30):18714-18919.

  12. Hanssen KF, Dahl-Jorgensen K, Lauritzen T. Diabetic control and microvascular complications: The near normoglycemic experience. Diabetología 1986; 29:677-684.

  13. Brownlee M, Cerami AJ, Vlassara H. Advanced glycosylation end –products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315-1321.

  14. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405-412.

  15. Portero-Otin M, Pamplona R, Bellmunt MJ, Bergua M, Prat J. Glycaemic control and in vivo non oxidative Maillard reaction: urinary excretion of pyrraline in diabetes patients. Eur J Clin Invest. 1997;27:767-773.

  16. Fu MX, Wells-Knecht KJ, Blackledge JA, Lions TJ, Thorpe SR, Baynes JW. Glycation glycoxidation and crosslinking of collagen by glucose:kinetics, mechanisms and inhibition of late stages of the Maillard reaction. Diabetes 1994;43:676-683.

  17. Dunn JA, Patrick JS, Thorpe SR, Baynes JW. Oxidation of glycated proteins: age dependet accumulation of N-(carboximethyl) lysine in lens proteins. Biochemistry 1990;28:9464-9468.

  18. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein crosslink pentosidine. Glucose, fructose and ascorbate as pentosidine precursors. J Biol Chem 1991: 266:11649-11653.

  19. Dyer DG, Blackledge JA,Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo.J Biol Chem.1991;266:11654-11660.

  20. Bucala R, Makita Z, Koschinski T, Cerami A, Vlassara H. Lipid advanced glycosylation. Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993;90:6434-6438.

  21. Petes TD, Farber RA, Tarrant GM, Holliday R. Altered rate of DNA replication in aging human fibrolblast cultures. Nature 1974;251:434-436.

  22. Monier VM, Cerami A. Nonenzymatic glycosylation and browning of proteins in vivo.En: Maillard reaction in foods and nutrition. American Chemical Society Symposium Series No.215 Washington DC,The American Chemical Society 1983. pp431-439.

  23. Dier DG, Dunn JA, Thorpe SR, Bilie KE, Lyons TJ, McCance DR, Baynes JW. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993;91:2463-2469.

  24. Monier VM, Cerami A. Nonenzymatic glycosylation and browning of proteins in vivo. In: The Maillard reaction in foods and nutrition. Waller GR, Feather MS (Eds.) American Chemical Society Symposium Series No. 215. The American Chemical Society. Washington DC. 1983, pp 431-439.

  25. Higgins PJ, Bunn HF. Kinetic analysis of the nonenzymatic glucosylation of hemoglobin. J Biol Chem.1981;256:5204-5208.

  26. Reser KM. Nonenzymatic glycation of collagen in aging and diabetes. Exp Biol Med.1991;196(1):17-29.

  27. Sell DR, Monier UV. End –stage renal disease and diabetes catalyzed deformation of a pentose-derived crosslink from aging human collagen.J Clin Invest.1990;75:380-384.

  28. Vlassara H. Recent progress on the biologic and clinical significance of advanced glycosylation end products. J Lab Clin Med. 1994;19-30.

  29. Westwood ME, Thornalley PJ. Glycation and advanced glycation endproducts. In: The Glycation Hypotesis of Atherosclerosis. Colaco C (Ed.) Landes Bioscience and Chapman & Hall. New York, USA 1997, pp 57-87.

  30. Brinkmann EB, Dehenhard TP, Thorpe SR, Baynes JW. Role of the Maillard reaction in aging of tissue proteins. J Biol Chem 1998;273(30):18714-18719.

  31. Pongor S, Ulrich PC, Bencsath A, Cerami A. Aging of proteins: Isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Biochemistry 1984;81: 2684-2688.

  32. Miyata HK, Yasuda T, Takeda A, Yasuda Y, Maeda K, Sobue G, Kurokawa K. Immunohistochemical localization of advanced glycation end products, pentosidine and carboxymethyl-lysine in lipofucsin pigments of Alzheimer´s disease and aged neurons, Biochem Biophys Res Commun.1997;236:327-332.

  33. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A. Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;91:9441-9445.

  34. Bucala R, Makita Z, Koschinsky T, Cherami A, Vlassara H. Lipid advanced glycosylation. Pathway for lipid oxidation in vivo. Proc Natl. Acad Sci USA 1993;90:6434-6438.

  35. Picard S, Parthasathy S, Fruebis J, Witztum JL. Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad. Sci USA 1991; 89:6876-6880.

  36. Bucala R, Model P, Cerami A. Modifications of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci USA 1984;81:105-109.

  37. Price GB, Modak SP, Makinodan T. Age-associated changes in the DNA of mouse tissue. Science 1971;171:917-920.

  38. Thornalley PJ. Cell activation by glycated proteins. Age receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 1998;44(7):1013-1023.

  39. Vlassara H, Brownlee M, Cerami A. High-affinity receptor-mediated uptake and degradation of glucose modified proteins: A potential mechanism for the removal of senescent macromolecules . Proc Natl Acad Sci.USA 1985; 82:5588-5592.

  40. Schmidt A-M, Hori M, Chen JX, Li JF Carndall J, Zjang J, Cao R, Yan DS, Brett J, Stern D. Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM) in cultured human endothelial cells in mice. J Clin Invest 1995; 96:1395-1403.

  41. Abordo EA,Westwood ME, Thornalley PJ. Synthesis and secretion of macrophage colony stimulating factor by mature human monocytes and human serum albumin derivatives modified with methyl glyoxal and glucose-derived advanced glucose endproducts. Immunol Lett 1996; 53:7-13.

  42. Kirstein M, Brett J, Radoff S Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of PDGF:role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 1990; 87:9010-9014.

  43. McCance DR, Dyer DG, Dunn JA, Baiue KE, Thorpe SR, Baynes JW, Lyons TJ. Maillard reactions products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993;91:2470-2478.

  44. Lyons TJ, Silvestri G, Dunn DG, Baynes JW. Role of glycation in modification of lens crystallins in diabetic and non-diabetic senile cataracts. Diabetes 1991;40:1010-105.

  45. Vlassara H, Fuh H, Makita Z,Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc Natl Acad Sci USA 1992;89:12043-12047.

  46. Miyata T, Oda O, Inagi R, Lida Y, Araki N, Yamada N, Horiuchi S,Taniguchi N,Maeda K. b2-Microglobulin modified with advanced glycation endproducts is a major component of haemodialysis-associated amyloidosis. J Clin Invest 1993;92:1242-1252.

  47. Schmidt A-M, Mora R, Cao R, Yan S-D Brett J, Ramakrishnan R, Tsang TE, Simonescu M, Stern D.The endothelial binding site for advanced glycation endproducts consist of a complex: An integral membrane protein and a lactoferrin-like polipeptide. J Biol Chem 1994;269:9882-9888.

  48. Neper M, Schmidt A-M, Brett J, Yan SD, Wang F, Pan Y-CE, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation endproducts of proteins. J Biol Chem 1992;267:14998-15004.

  49. Brett J, Schmidt A-M, Yann SD, Zou S, Weideman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A, Migheli A, Stern D. Survey of the distribution of a newly characterized receptor for advanced glycation endproducts in tissues. Am J Pathol 1993;143:1699-1712.

  50. Renard C, Cappey O, Wautier MP, Nagashima M,Lundh ER, Morser J, Zhao L, Schmid A-M, Schermann J-M, Wautier JL. Recombinant advanced glycation endproduct receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol 1997;52:54-62.

  51. Khalifah RG, Baynes JW, Hudson BG. Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999;257:251-258.




2020     |     www.medigraphic.com